Explore Our Network

Advanced Virology specializes in high-fidelity production and engineering of research-grade virus stocks using reverse genetics. The company supports customizable solutions across a broad range of viral families—including wild-type, chimeric, and reporter-expressing viruses. Comprehensive quality assurance and documentation protocols are applied to each batch. Custom services enable the development of tailored virus variants, molecular tags, and reporters to meet research and assay needs.

Ambient Biosciences is a global leader in biostabilization, dedicated to eliminating cold chain reliance and improving global health equity through innovative biomolecule stabilization technology. Their patented Capillary-Assisted Vitrification (CAV) process enables room-temperature storage and shipping of sensitive reagents and biomolecules, offering a superior alternative to traditional lyophilization and cryopreservation. With a values-driven, diverse team of scientific experts and visionary leaders, Ambient Biosciences is committed to transforming laboratory operations, reducing costs and waste, and making life sciences more accessible and sustainable worldwide.

Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.

Battelle is an independent nonprofit organization dedicated to advancing science and technology to address the world's most pressing challenges. With over 90 years of experience, Battelle transforms knowledge into profound innovation, reinvesting its proceeds into scientific advancement and STEM education. The organization operates across various markets, including health, national security, environment, infrastructure, and industry, providing solutions through limitless innovation and expertise in scientific and engineering disciplines.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.

Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.

Centivax is a universal immunity company, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that deliver universal protection against entire classes of diverse targets. The lead clinical candidate for influenza—featured in The New Yorker, the Netflix docuseries Pandemic: How to Prevent an Outbreak, and other outlets—addresses a greater than $7 billion global flu market, with follow-on programs spanning a growing pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a universal antivenom. This growing portfolio underscores the technology's broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as cancer, autoimmune conditions, cardiovascular and neurodegenerative disease. Centivax is headquartered in South San Francisco, California. Visit www.centivax.com and follow @Centivax on X.

Cepheid is a global leader in molecular diagnostics, dedicated to improving healthcare by developing, manufacturing, and marketing automated, easy-to-use molecular systems and tests. Their mission is to provide rapid, accurate, and actionable genetic testing for a wide range of infectious diseases, oncology, and human genetics. Cepheid's flagship GeneXpert System delivers scalable, sample-to-answer PCR testing for institutions of any size, supporting both centralized and decentralized care. The company is committed to expanding access to high-quality diagnostics worldwide, supporting public health initiatives, driving innovation in molecular testing, and advancing sustainability and responsible business practices.

Ceres Nanosciences, Inc. is a privately held company based in Northern Virginia, specializing in the development and commercialization of Nanotrap® hydrogel particle technology. Their mission is to deliver innovative products powered by Nanotrap Technology to address life science needs and provide better patient outcomes. Ceres' products enable the capture, concentration, and preservation of low-abundance analytes from diverse biological and environmental samples, supporting applications in diagnostics, research, and public health surveillance. The company is ISO 9001:2015 certified and collaborates with leading research institutions, public health agencies, and industry partners to advance global health security and biosecurity. Ceres has established a national network of Wastewater-based Epidemiology Centers of Excellence and has received significant funding from the NIH RADx initiative and other organizations to expand its impact in underserved communities. Their technology is widely adopted for wastewater-based epidemiology, proteomics, and nucleic acid analysis, with a strong focus on supporting public health monitoring, early detection of infectious diseases, and environmental bio-surveillance.

The Clemson University Research Foundation (CURF) is dedicated to advancing the research enterprise at Clemson University by connecting faculty and students with industry partners. CURF facilitates the commercialization of university technologies, supports research collaboration, and promotes innovation through various funding and support programs.

CureLab Veterinary is a biotechnology company focused on the development of gene-based therapies targeting cancer and chronic inflammatory diseases in companion animals, such as dogs, cats, and horses. Utilizing advances in comparative medicine and translational immunology, the company applies a plasmid-based platform to stimulate anti-cancer immune responses, modulate tumor microenvironments, and mitigate chronic inflammation. Clinical research leverages academic partnerships and a robust intellectual property portfolio, pursuing efficient regulatory approval pathways in major markets, including the US and Europe. Recent studies suggest broader applications in pain management and cross-species translational potential.

Diadem Biotherapeutics is a biotechnology company focused on developing first- and best-in-class therapeutics by engineering extracellular vesicles to modulate immune responses. Their mission is to innovate beyond existing solutions to address unmet medical needs, leveraging expertise in immunology, bioengineering, and drug development. The company’s proprietary DECOSTAR™ platform enables precise costimulatory activation or repression of immune cells, targeting a range of diseases including cancer and autoimmunity.

The Institute for Biohealth Innovation (IBI) at George Mason University unites over 300 faculty and thousands of students across 34 departments to advance human health and well-being through innovative research. The IBI focuses on major health challenges, including infectious diseases, cancer, brain and behavior, and cardiovascular health, collaborating with national and international partners to implement solutions that enhance health outcomes.

Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.

Goodrich Lab at Colorado State University focuses on research for treating and preventing disease transmission, with emphasis on vaccine development and pathogen inactivation using photochemical methods. The lab conducts both fundamental and translational research ranging from device prototyping and animal studies to clinical trial readiness. Disease targets include SARS-CoV-2, tuberculosis, various strains of influenza, African swine fever, and cancer immunotherapy.